FDA again turned back Capricor Therapeutics’ Duchenne cell therapy deramiocel, citing “serious data integrity violations” that the agency said compromised study findings. The decision marks the therapy’s second rejection since 2025, according to the FDA statement described in the report. The development puts additional pressure on the company as it faces the prospect of re-running work to address the agency’s data concerns. For investors and the Duchenne community, the latest FDA action underlines how data quality issues can become determinative even when programs are built on advanced cell-based approaches. Capricor will now need to decide whether to pursue a resubmission strategy or revise the evidence package, while the wider cell therapy field watches for any emerging patterns in FDA’s handling of integrity-related findings.